Tdpoz4 Inhibitors
Tdpoz4 inhibitors are a class of chemical compounds characterized by their specific interaction with the Tdpoz4 enzyme, a protein whose activity is crucial in a particular biological pathway. These inhibitors are designed to bind to the active site or another relevant domain of the Tdpoz4 enzyme, blocking its action by either competitive or non-competitive means. In competitive inhibition, the inhibitor resembles the enzyme's natural substrate and competes for binding at the active site, while in non-competitive inhibition, the inhibitor binds to a different part of the enzyme, causing a conformational change that reduces the enzyme's activity. The specificity of Tdpoz4 inhibitors is a result of meticulous molecular design, which ensures that the interaction with the enzyme is both strong and selective, thereby modulating the function of Tdpoz4 without significantly affecting other enzymes.
The development and study of Tdpoz4 inhibitors are rooted in a deep understanding of the enzyme's structure and function. Structural biology techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy provide detailed insights into the three-dimensional configuration of Tdpoz4, allowing chemists to tailor inhibitors that fit like a lock and key. The chemical composition of Tdpoz4 inhibitors often includes rings and chains that mimic the natural substrates or products of the Tdpoz4-catalyzed reaction. Additionally, these inhibitors may possess functional groups that engage in hydrogen bonding, electrostatic interactions, or hydrophobic contacts with the enzyme, which further stabilize the inhibitor-enzyme complex. The design process is typically iterative, with initial inhibitor prototypes being refined over multiple rounds of synthesis and binding assays to enhance their potency and selectivity for Tdpoz4.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), Wortmannin can suppress the PI3K/Akt signaling pathway. Given that Tdpoz4 is a protein that may be downstream of Akt signaling, inhibition of PI3K could lead to reduced phosphorylation and activity of Akt, indirectly leading to decreased function of Tdpoz4. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of PI3K, LY294002 interferes with the PI3K/Akt pathway similarly to Wortmannin. By inhibiting this pathway, the phosphorylation and activation of downstream proteins like Tdpoz4 could be impaired, thus inhibiting its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can disrupt the mTORC1 signaling complex, Rapamycin would lead to a downregulation of downstream protein synthesis, which may include proteins like Tdpoz4 whose expression is dependent on mTORC1 signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK, PD98059 disrupts the MEK/ERK pathway. If Tdpoz4 functions downstream of the MEK/ERK pathway, inhibition by PD98059 could reduce its activation or expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of the c-Jun N-terminal kinase (JNK), SP600125 could prevent the activation of transcription factors that regulate the expression of Tdpoz4, thus leading to decreased levels of the protein. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor, SB203580 could inhibit the p38 MAPK pathway, potentially affecting the expression or function of Tdpoz4 if it is involved in stress or inflammatory response pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK inhibitor that can inhibit ERK activation. If Tdpoz4 operates within the MEK/ERK pathway, its function could be compromised by U0126 disruption of this signaling cascade. | ||||||
Casein Kinase I Inhibitor, D4476 | 301836-43-1 | sc-202522 | 1 mg | $99.00 | 6 | |
A casein kinase 1 inhibitor, D4476 could prevent phosphorylation events that are essential for Tdpoz4 stability or activity, assuming Tdpoz4 is a substrate for this kinase. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can prevent the degradation of ubiquitinated proteins. If Tdpoz4 is regulated by proteasomal degradation, Bortezomib could indirectly increase its levels, however, prolonged proteasome inhibition often leads to cellular stress and downregulation of protein synthesis which could eventually decrease Tdpoz4 levels. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Like Bortezomib, MG132 is a proteasome inhibitor. It would lead to a buildup of ubiquitinated proteins and could cause a stress response that reduces the synthesis of various proteins, potentially including Tdpoz4. | ||||||